Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Biocon's Pebrilzo gets EU nod for HER2-positive breast cancer treatment

The approval makes Biocon's pertuzumab the first biosimilar to receive EC marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach

Biocon's Pebrilzo gets EU nod for HER2-positive breast cancer treatment

We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.

Read the original at business-standard.com →

More in Health & Medicine

More from Wednesday 18 November →